QUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery. Strategic partnership with the Research Institute of Molecular Patholog ...
AllianceQUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery 24.10.2024 / 09:30 CET/CESTThe issuer is solely responsible for the content of this ...
The CEO of pharmaceuticals giant Roche said authorities should block the takeover of contract drug manufacturer Catalent ...
It’s important to maintain a temperature of 77 degrees or cooler, and above freezing, so efficacy is highest when the product ...
The Progressive Fibrosing Interstitial Lung Disease (PF-ILD) market is currently valued at USD 4,742.2 Million in 2023 and is ...
Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – is pleased to announce ...
Progressive pulmonary fibrosis (PPF) is an increasingly recognised condition, defined in 2022 to address the progression of ...
A persistent, often progressive, lung disease, COPD results from chronic inflammation that leads to structural changes ...
NEW YORK – Researchers have identified a gene signature that can predict whether early-stage breast cancer patients will ...
The medicine, which Novo sells as Rybelsus, cut the risk of cardiovascular complications by 14% when added to standard ...
The Global Non-Small Cell Lung Carcinoma (NSCLC) Market is on the brink of an extraordinary transformation, with market ...
An interim analysis from a long-term open-label extension study has underlined the clinical efficacy and safety of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback